OrganiGram Holdings Inc
TSX:OGI

Watchlist Manager
OrganiGram Holdings Inc Logo
OrganiGram Holdings Inc
TSX:OGI
Watchlist
Price: 1.45 CAD -5.23%
Market Cap: 183m CAD

EV/EBITDA
Enterprise Value to EBITDA

-1.7
Current
-2.4
Median
12.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.7
=
Enterprise Value
180m CAD
/
EBITDA
-105.7m CAD
EBITDA Growth EV/EBITDA to Growth
CA
OrganiGram Holdings Inc
TSX:OGI
Average EV/EBITDA: 435.1
Negative Multiple: -1.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.2
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.4
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
US
Merck & Co Inc
NYSE:MRK
9
9%
1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
12.6
2-Years Forward
EV/EBITDA
7.1
3-Years Forward
EV/EBITDA
3.5